CION Ameerpet
Radiation Therapy · Combining Treatments
The Abscopal Effect — Can Radiating One Tumour Shrink Another?
Occasionally, yes — and it is rare enough that no treatment plan is built around it. The abscopal effect is the name for a tumour shrinking somewhere the beam never reached, most often discussed in patients who are also receiving immunotherapy. It is real, it is documented, and it is not something any team can schedule, dose for or promise.
Medically reviewed by Dr. Venkata Sushma P, Radiation Oncologist, MBBS · MD (Radiation Oncology) · Last reviewed August 2026
- Real, but genuinely rare — still reported as individual published cases rather than as a predictable result — no guideline body recommends radiation given for this purpose outside a clinical trial.
- Nothing is being withheld from you — being told it cannot be planned for is not a lesser standard of care. It is the position reflected in NCCN, ASTRO and ESMO guidance today.
- Sequencing is a team decision — whether radiation runs before, during or after your systemic treatment depends on the site, the reason and how you are tolerating things. Never pause or restart anything on your own.
- Delivered at NABH-accredited partner centres — CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout; radiotherapy itself is delivered at a partner centre.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
What is the abscopal effect?
The abscopal effect is when radiation aimed at one tumour is followed by shrinkage of a different tumour somewhere else in the body — in an area the beam never touched. The name is Latin: ab, away from, and scopus, target. It is documented. It is also uncommon.
The leading explanation is immune. Radiation damages cancer cells inside the treated area, and damaged cells release fragments of themselves. Those fragments can make the tumour easier for the immune system to recognise as something to act against. If the immune system is already primed — or is being supported by immunotherapy — that recognition is not confined to the spot that was treated. It can, in principle, travel.
That is the theory in one paragraph, and it is why the idea captured so much attention. Two things are worth separating early. The mechanism is plausible and actively researched. The event — a measurable tumour outside the field actually shrinking — is rare, unpredictable, and not something a plan is built around.
Your radiotherapy is delivered at an NABH-accredited partner centre; CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout.
Did you know?
The word was coined in 1953 by the British radiobiologist R. H. Mole, who joined the Latin ab (away from) and scopus (target) to name an effect seen away from the treated area. It then sat quietly in the literature for roughly half a century as a curiosity, and became an active research question again only when modern immunotherapy reached the clinic.
The honest answer
How often does the abscopal effect actually happen?
Rarely. Decades after it was named, individual patients are still written up and published one case at a time. That fact alone tells you the frequency. Something that happened routinely would not still be reported as a notable event in the medical literature.
Randomised studies that added radiation to immunotherapy have gone looking for it deliberately. They have not produced a consistent, repeatable increase in responses at untreated sites that changed standard practice. Where encouraging signals appeared, they appeared in particular subgroups and remain a research question rather than a settled finding.
This is where the internet and the clinic part company. Online, the abscopal effect is one of the most over-shared ideas in cancer care: a striking scan, a compelling story, a headline that implies a general rule. In an oncology clinic it is understood as a real but exceptional event. Both of those can be true at once, and holding both is the accurate position.
No major guideline body — NCCN, ASTRO or ESMO — recommends giving radiation for the purpose of producing an abscopal response outside a clinical trial. That is not caution for its own sake. It reflects what the evidence currently supports.
The useful planning assumption is that it will not happen to you, and that it is a welcome bonus if it does. Anyone offering it as a reason to choose one centre over another is ahead of the evidence.
Side by side
What you will read online vs what is actually established
Most of the confusion around the abscopal effect is not invented — it is a real idea stretched past what the evidence carries. Here is each common claim next to the current position.
| What you will read online | What is actually established |
|---|---|
| Radiation wakes up the immune system to attack cancer everywhere in the body | Radiation can release tumour material the immune system may recognise. Whether that produces shrinkage elsewhere is unpredictable and uncommon. |
| The abscopal effect is common now that immunotherapy exists | It is not. It is still reported as individual cases. Interest rose sharply with immunotherapy; frequency did not follow to the same degree. |
| There is a special dose or schedule that reliably triggers it | Several dose and schedule approaches have been studied. None is established as reliably producing it. This remains an open research question. |
| My centre should radiate a tumour just to set it off | Radiation is given when there is an independent reason to treat that site. Hoping for an out-of-field response is not, on its own, an accepted reason. |
| If it does not happen, my radiation failed | No. Your radiation is judged on the target that was actually treated. An abscopal response was never the goal it was measured against. |
| It only happens alongside immunotherapy | Most reported cases involve immune-active treatment, but the effect was described long before modern immunotherapy existed. |
| I should ask for radiation and immunotherapy together to improve my odds | Combining them is done for defined clinical reasons and needs careful sequencing. That judgement belongs to your treating team, not to a search result. |
| Where does treatment actually happen? | At an NABH-accredited partner centre. CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout. |
This table describes the general position as of August 2026. What applies to your own case depends on your cancer type, your stage and your current treatment — ask your radiation oncologist directly.
Decision framework
Can my treatment be planned around the abscopal effect?
No. It cannot be scheduled, dosed for or promised. Radiation is planned around the site being treated and the reason for treating it — relieving a symptom, controlling disease at that spot, or treating a small number of secondary sites with intent. An out-of-field response is not a reason a plan can rest on.
If your team declines to add radiation purely in the hope of one, that is not a lesser standard of care and nothing is being withheld from you. It is the position reflected in current guideline thinking. A centre that promises you an abscopal response is telling you something the evidence does not support.
What you can usefully do is change the question. Instead of asking whether radiation might set off a distant response, ask the three questions your team is actually answering:
One — is there an independent reason to treat this site? Pain, pressure, bleeding, a risk of fracture, disease at a small number of spots that is worth treating directly. If yes, radiation is on the table on its own merits.
Two — does the sequence with my systemic treatment make sense? This is about order and timing, not about hope. It is decided by your medical oncologist and radiation oncologist together.
Three — what does the added risk look like for me? Which organs sit in the treated area, what your current treatment already asks of them, and how you have tolerated things so far.
Answer those three and you have a real decision. An abscopal response, if it ever appears, arrives on top of a plan that made sense without it.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Ask about sequencing before anything is paused or started
The order of radiation and systemic treatment is a clinical decision, not a reading exercise. A radiation oncologist can talk you through how it would be decided in your case. Free, confidential, no commitment to start treatment.
Step by step
How is the order of radiation and systemic treatment decided?
Sequencing is not guesswork and it is not decided from an article. This is the sequence of decisions that sits behind the date you are eventually given.
The whole picture goes to the team
Your scans, pathology, current treatment and how you are tolerating it are reviewed together, usually in a multidisciplinary tumour board rather than by one doctor alone.
The reason for radiation is defined first
Before any timing is discussed, the team settles what the radiation is for: a symptom, local control, or treating a limited number of sites with intent.
Your systemic treatment is mapped onto a calendar
Cycle dates, how long each agent stays active in the body and when your next scan falls all go on the same timeline as the proposed radiation course.
Overlapping side-effect risks are checked
The team looks at which organs sit inside the treatment area and what your current treatment already asks of those same organs — lungs, bowel, skin, liver, kidneys.
A hold, or no hold, is decided — by the team
Sometimes systemic treatment runs straight through. Sometimes a short planned gap is built around radiation. Sometimes radiation waits. This decision is never yours to make alone.
Planning scan and plan build
You are scanned in the treatment position, the treatment area and the organs at risk are outlined, the dose is prescribed, and a medical physicist checks the plan before it is released.
Treatment, with monitoring in both directions
Radiation is delivered at the partner centre while your medical oncology team keeps watching for side effects that could belong to either treatment.
Restart and review
If anything was paused, the team decides when it restarts, based on how you recovered from the radiation course rather than on a fixed rule.
If you are coordinating a relative’s care from another city or country, this is the sequence to ask about on a call. Ask what the radiation is for, whether anything is being held, and who is making that call.
Behind the decision
What your team is weighing when they choose the order
None of these six is about the abscopal effect. All six are about you.
The reason
Why this site, and how urgently
Pain, pressure or bleeding moves radiation earlier. A site being treated for control alone can usually wait for a better window.
Overlap
Lung inflammation risk
Both radiation to the chest and some systemic treatments can inflame lung tissue. When the treated area includes lung, this shapes both timing and technique.
Overlap
Skin, bowel and mucosa
Reactions in skin, the bowel lining or the mouth can come from either treatment. Overlapping them makes a reaction harder to attribute and slower to settle.
Timing
How long a treatment stays active
Some systemic treatments keep acting for weeks after a dose. A gap on paper is not always a gap in the body, and the team plans around that.
Practical
Where each treatment happens
Radiotherapy runs daily at an NABH-accredited partner centre. Travel, accommodation and your systemic treatment dates have to fit one calendar.
You
How you are doing right now
Blood counts, weight, energy and how you handled your last cycle carry real weight. A theoretically ideal sequence you cannot tolerate is not the right one.
Safety
Is it dangerous to have radiation while I am on immunotherapy?
It is done routinely in appropriate cases, and it is not automatically dangerous — but it is not neutral either. The concern is overlapping side effects rather than a direct clash between the two treatments. Immunotherapy can inflame the lungs, bowel, skin and other organs. Radiation inflames whatever tissue sits inside the treated area.
When both act on the same region, two things get harder: telling which treatment caused a reaction, and settling that reaction once it starts. This is exactly why the sequence is decided by your medical oncologist and radiation oncologist together, with the treated area, your organ function and your recent side effects all in front of them.
The single most important thing you can do is not adjust anything yourself. Do not skip a cycle, delay a dose or stop attending radiation to create a gap you read about. If you believe the order is wrong, say so — ask for the reasoning, or ask for a second opinion. Both are reasonable. Acting alone is not.
CION Cancer Clinics does not own or operate a linear accelerator, CyberKnife, Gamma Knife or proton facility, and is not itself NABH-accredited. Your radiotherapy is delivered at an NABH-accredited partner centre; CION coordinates your treatment plan, your oncology team and your care throughout.
Tell your team promptly if any of these appear
- New breathlessness or a new dry cough — particularly if your chest is being treated or has been treated recently. Do not wait for your next appointment; call your team.
- Diarrhoea that is persistent or worsening — report it rather than managing it at home, especially while on immunotherapy.
- A rash that is spreading, blistering or painful — distinguishing a skin reaction from the treatment area from a wider reaction matters, and needs to be seen.
- Fever, or feeling suddenly and unusually unwell — call the helpline on 1800 202 8726 rather than waiting it out.
- Anything you were told to watch for — your team will have named specific things for your case. Those instructions override anything on a website, including this one.
Questions worth asking at your next appointment
- What is this radiation for? — you should get a specific answer: this symptom, this site, this intent.
- Is any of my current treatment being held around it, and for how long? — ask for the reasoning, and who made the decision.
- Which organs are inside the treatment area? — this is what shapes the overlapping-side-effect discussion.
- Who do I call if something changes mid-course? — get one number and one name before you start.
- Can I have the plan and the estimate in writing? — any cost figure quoted to you is indicative only, as of August 2026, and varies with technique, number of sittings and the centre delivering treatment.
Bring the article with you
One conversation usually settles what is hope and what is evidence
Whether you found the abscopal effect online or a relative abroad sent it to you, a radiation oncologist can explain in plain terms what it would and would not change in your own plan.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
The abscopal effect — your questions answered
What is the abscopal effect?
The abscopal effect is when radiation aimed at one tumour is followed by shrinkage of a different tumour elsewhere in the body, in an area the beam never touched. The name comes from Latin: ab, meaning away from, and scopus, meaning target. The leading explanation is immune. Radiation damages tumour cells and releases fragments of them, which can make a tumour easier for the immune system to recognise. If the immune system is already active, or is being supported by immunotherapy, that recognition can in principle act at distant sites too. It is documented in the medical literature, and it is uncommon.
How often does the abscopal effect actually happen?
Rarely. Decades after the effect was named, individual patients are still written up and published one case at a time, which tells you how unusual it remains. Randomised studies that added radiation to immunotherapy have looked for a reliable increase in responses at untreated sites and have not produced a consistent finding that changed standard practice. No major guideline body, including NCCN, ASTRO and ESMO, recommends giving radiation for the purpose of producing an abscopal response outside a clinical trial. The honest planning assumption is that it will not happen, and that it is a bonus if it does.
Can my radiation be planned to trigger an abscopal effect?
No. It cannot be scheduled, dosed for or promised. Radiation is planned around the site being treated and the reason for treating it, such as relieving a symptom, controlling disease at that spot, or treating a small number of secondary sites with intent. If your team declines to add radiation purely in the hope of an abscopal response, that is not a lesser standard of care. It is the position guideline bodies currently take. Ask instead whether there is an independent reason to treat a site, and what the sequencing with your systemic treatment would look like.
Is it safe to have radiation while I am on immunotherapy?
It is done, and it is not automatically dangerous, but it is not neutral either. The main concern is overlapping side effects rather than a direct clash. Immunotherapy can inflame the lungs, the bowel, the skin and other organs, and radiation can inflame whatever tissue sits inside the treated area. When both act on the same region, reactions can be harder to tell apart and slower to settle. That is why the decision sits with the treating team, with the treated area, your organ function and your recent side effects all on the table. Report new breathlessness, a new dry cough, a spreading rash or persistent diarrhoea promptly.
Should radiation come before, during or after immunotherapy?
There is no single correct order, and it is not a decision to make from an article. It depends on why radiation is being given, how urgent it is, which part of the body is being treated, what your current treatment is doing and how you are tolerating it. Sometimes systemic treatment continues straight through a short course of radiation. Sometimes a planned gap is built around it. Sometimes radiation is deliberately delayed. Your medical oncologist and radiation oncologist decide this together, usually in a tumour board discussion. Never pause, delay or restart any treatment on your own to try to line them up.
A relative sent me an article about the abscopal effect. Is it worth asking about?
Yes, bring it to your consultation. It is a genuine phenomenon and a legitimate research question, so asking is reasonable and no good team will mind. What to expect is a measured answer: that it is real, that it is rare, that it cannot be planned for, and that the order of your treatments is decided on other grounds. Families coordinating care from outside India often see confident claims online that run ahead of the evidence. Print the article, bring it, and ask what it would change in your own plan. Usually the answer is nothing, and knowing that is worth the question.
This page explains the abscopal effect and the sequencing of radiation with systemic treatment in general terms. It is not a substitute for guidance from your own oncology team about your diagnosis and your treatment plan.